Report error Found 66 of ic50 data for polymerid = 50004581,50006282
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 15.8nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 31.6nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 31.6nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 50.1nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 79.4nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 126nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 158nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 200nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 251nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 316nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 370nMAssay Description:PatchXpress 7000A Solutions are used to record HCN currents.More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 398nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 398nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 398nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 398nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 400nMAssay Description:PatchXpress 7000A Solutions are used to record HCN currents.More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 500nMAssay Description:PatchXpress 7000A Solutions are used to record HCN currents.More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 631nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 631nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 631nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+3nMAssay Description:PatchXpress 7000A Solutions are used to record HCN currents.More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.26E+3nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.40E+3nMAssay Description:PatchXpress 7000A Solutions are used to record HCN currents.More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.58E+3nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.80E+3nMAssay Description:PatchXpress 7000A Solutions are used to record HCN currents.More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 2.00E+3nMAssay Description:PatchXpress 7000A Solutions are used to record HCN currents.More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 2.20E+3nMAssay Description:PatchXpress 7000A Solutions are used to record HCN currents.More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 2.40E+3nMAssay Description:Sophion Qube Solutions are used to record HCN currents.More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 2.51E+3nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 2.80E+3nMAssay Description:Sophion Qube Solutions are used to record HCN currents.More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 2.90E+3nMAssay Description:Sophion Qube Solutions are used to record HCN currents.More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 2.90E+3nMAssay Description:Sophion Qube Solutions are used to record HCN currents.More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 3.00E+3nMAssay Description:PatchXpress 7000A Solutions are used to record HCN currents.More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 3.00E+3nMAssay Description:Sophion Qube Solutions are used to record HCN currents.More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 3.20E+3nMAssay Description:Sophion Qube Solutions are used to record HCN currents.More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 3.40E+3nMAssay Description:PatchXpress 7000A Solutions are used to record HCN currents.More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 3.80E+3nMAssay Description:PatchXpress 7000A Solutions are used to record HCN currents.More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 4.20E+3nMAssay Description:Sophion Qube Solutions are used to record HCN currents.More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 4.40E+3nMAssay Description:PatchXpress 7000A Solutions are used to record HCN currents.More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 4.50E+3nMAssay Description:PatchXpress 7000A Solutions are used to record HCN currents.More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 4.60E+3nMAssay Description:PatchXpress 7000A Solutions are used to record HCN currents.More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 5.10E+3nMAssay Description:Sophion Qube Solutions are used to record HCN currents.More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 5.30E+3nMAssay Description:Sophion Qube Solutions are used to record HCN currents.More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 7.60E+3nMAssay Description:Sophion Qube Solutions are used to record HCN currents.More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 8.00E+3nMAssay Description:PatchXpress 7000A Solutions are used to record HCN currents.More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 8.70E+3nMAssay Description:PatchXpress 7000A Solutions are used to record HCN currents.More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 8.90E+3nMAssay Description:PatchXpress 7000A Solutions are used to record HCN currents.More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.58E+4nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.58E+4nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.69E+4nMAssay Description:Sophion Qube Solutions are used to record HCN currents.More data for this Ligand-Target Pair
